Achilles Therapeutics Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Achilles Therapeutics Inc. | ACHL - NASDAQ |
$17.00-$19.00 | $18.00 | $18.00 | 9.75 million ADSs | 3/31/2021 |
| JP Morgan, BofA Securities, Piper Sandler | ||||||
Co-Manager(s): Chardan, Oppenheimer & Co., Kempen & Co | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-03-01 Terms Added 2021-03-25 | ||||||
Achilles Therapeutics Inc. Quote & Chart - Click for current quote - ACHL
IPO Boutique aggregates information on public companies and private companies, such as "ACHL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Achilles Therapeutics Inc. (adapted from Achilles Therapeutics Inc. prospectus):
They are a clinical stage immuno-oncology biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumors.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical stage immuno-oncology biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumors.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ACHL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.